Development of Targeted Agents and Companion Diagnostics

Abstract

This article summarizes a presentation made at the joint BIA/MHRA conference, “Challenges of Development of Targeted Agents and Companion Diagnostics,” in London in March 2011. It focuses on the challenges the pharmaceutical industry is facing with the development of targeted agents in the field of oncology, in parallel with the challenges associated with the identification and development of the necessary diagnostic tools to support patient selection for personalized therapy. This article will encompass clinical, technical, and regulatory aspects.